The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment

Author(s): Frank Weidemann, Georg Ertl, Christoph Wanner, Johannes Krämer

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 4 , 2015

Become EABM
Become Reviewer
Call for Editor


Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency. The intracellular storage of globotriaosylceramides in different tissues and organs leads to a multisystemic disease affecting kidneys, nervous system and the heart. Fabry cardiomyopathy is frequent and leads to concentric left-ventricular hypertrophy. Typical pattern in advanced stages is myocardial replacement fibrosis, first localized to mid myocardial layers of postero-lateral basal myocardium and then spreading to transmural fibrosis.Long term prognosis is dependent on timely initiation of specific and concomitant therapies, while therapy in advanced stages is only able to stabilize the organ affection.

This review describes the characteristics of Fabry cardiomyopathy, shows the clinical assessment of cardiac involvement and highlights therapeutic issues aiming at the best outcome for patients with Fabry disease.

Keywords: Fabry disease, cardiomyopathy, monitoring, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [473 - 478]
Pages: 6
DOI: 10.2174/138161282104141204142643
Price: $65

Article Metrics

PDF: 77